Responding to the Clopidogrel Warning by the US Food and Drug Administration
- 3 August 2010
- journal article
- editorial
- Published by Wolters Kluwer Health in Circulation
- Vol. 122 (5) , 445-448
- https://doi.org/10.1161/circulationaha.110.973362
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent PlacementCirculation, 2010
- Finding the missing heritability of complex diseasesNature, 2009
- Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel TherapyJAMA, 2009
- A population-based study of the drug interaction between proton pump inhibitors and clopidogrelCMAJ : Canadian Medical Association Journal, 2009
- Cytochrome P-450 Polymorphisms and Response to ClopidogrelNew England Journal of Medicine, 2009
- Genetic Determinants of Response to Clopidogrel and Cardiovascular EventsNew England Journal of Medicine, 2009
- Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort studyThe Lancet, 2009
- HLA-B*5701 Screening for Hypersensitivity to AbacavirNew England Journal of Medicine, 2008
- PharmGKB: Understanding the Effects of Individual Genetic VariantsDrug Metabolism Reviews, 2008
- Prasugrel versus Clopidogrel in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 2007